Drug Trial Radar · NCT02836873
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
Last checked: Nov 20, 2026Latest source record: Jun 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
312
Actual
Start
Sep 23, 2016
Primary completion
Jan 11, 2018
Study completion Jan 11, 2018
Sponsor
- Lead sponsor
- TheracosIndustry
- Sponsor type
- Industry
- First posted
- Jul 19, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of oral administration of bexagliflozin at 20 mg versus placebo in subjects with T2DM, moderate renal impairment and inadequate glycemic control.
Conditions
- Type 2 Diabetes Mellitus
Interventions
BexagliflozinDrug
Bexagliflozin tablet, 20 mg
PlaceboDrug
Placebo (inactive) tablet to match the active comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c at 24 WeeksTime frame: 24 weeks
Locations
56 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Fresno, California
Research Site
La Palma, California
Research Site
Lincoln, California
Research Site
Riverside, California
Research Site
Sacramento, California
Research Site
San Dimas, California
Research Site
Monument, Colorado
Research Site
Norwalk, Connecticut
Research Site
Hollywood, Florida
Research Site
Tampa, Florida
Research Site
West Palm Beach, Florida
Research Site
Paducah, Kentucky
Research Site
Auburn, Maine
Research Site
Rockport, Maine
Research Site
Nashua, New Hampshire
Research Site
The Bronx, New York
Research Site
Stow, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Austin, Texas
Research Site
Austin, Texas
Research Site
North Richland Hills, Texas
Research Site
Round Rock, Texas
Research Site
San Antonio, Texas
Research Site
Dijon, France
Research Site
Paris, France
Research Site
Paris, France
Research Site
Paris, France
Research Site
Pierre-Bénite, France
Research Site
Poitiers, France
Research Site
Vénissieux, France
Research Site
Atsugi-shi, Kanagawa, Japan
Research Site
Kamakura-shi, Kanagawa, Japan
Research Site
Kawasaki-shi, Kanagawa, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Kyoto, Kyoto, Japan
Research Site
Kyoto, Kyoto, Japan
Research Site
Kawagoe-shi, Saitama, Japan
Research Site
Kawaguchi-shi, Saitama, Japan
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.